» Articles » PMID: 8024008

ANG II Receptor Blockade Prevents Ventricular Hypertrophy and ANF Gene Expression with Pressure Overload in Mice

Overview
Journal Am J Physiol
Specialty Physiology
Date 1994 Jun 11
PMID 8024008
Citations 61
Authors
Affiliations
Soon will be listed here.
Abstract

There is increasing evidence that the renin-angiotensin system may play a important role in cardiac hypertrophy. To assess the role of angiotensin II in the induction of cardiac hypertrophy, three groups of adult mice were subjected to left ventricular pressure overload by transverse aortic constriction (TAC). For the next 7 days the groups received either the specific angiotensin II subtype 1 receptor (AT1) antagonist (losartan, 1.05 g/l; n = 17), an angiotensin enzyme inhibitor (captopril, 2 g/l; n = 17), or no treatment (n = 22) administered in the drinking water and compared with three similarly treated sham-operated groups (n = 7 each). TAC resulted in a significant increase in heart weight-to-body weight ratio (0.634 +/- 0.087 vs. 0.525 +/- 0.039, g/g x 100, P < 0.05), which was prevented by losartan (0.506 +/- 0.069, g/g x 100, P < 0.0001) despite similar hemodynamic load (proximal systolic pressure 146 +/- 31 vs. 136 +/- 32 mmHg, untreated vs. losartan, P = NS). Proximal systolic pressure was positively correlated with the development of ventricular hypertrophy. In the presence of AT1-receptor blockade, the increase in heart weight-to-body weight ratio at any given systolic pressure was significantly attenuated compared with untreated TAC mice. The increase in heart weight-to-body weight ratio was also significantly attenuated by captopril compared with untreated banded controls (0.542 +/- 0.091, g/g x 100, P = 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Piezo1 is the cardiac mechanosensor that initiates the cardiomyocyte hypertrophic response to pressure overload in adult mice.

Yu Z, Gong H, Kesteven S, Guo Y, Wu J, Li J Nat Cardiovasc Res. 2024; 1(6):577-591.

PMID: 39195867 PMC: 11358016. DOI: 10.1038/s44161-022-00082-0.


Exploring the implications of blocking renin-angiotensin-aldosterone system and fibroblast growth factor 23 in early left ventricular hypertrophy without chronic kidney disease.

Watanabe K, Fujii H, Okamoto K, Kono K, Goto S, Nishi S Front Endocrinol (Lausanne). 2024; 14:1276664.

PMID: 38174329 PMC: 10762797. DOI: 10.3389/fendo.2023.1276664.


Effects of the angiotensin-converting enzyme inhibitor captopril on occlusal-disharmony-induced cardiac dysfunction in mice.

Ito A, Ohnuki Y, Suita K, Matsuo I, Ishikawa M, Mitsubayashi T Sci Rep. 2023; 13(1):19927.

PMID: 37968296 PMC: 10651878. DOI: 10.1038/s41598-023-43099-6.


New drug discovery of cardiac anti-arrhythmic drugs: insights in animal models.

Sharma A, Singh S, Bhat M, Gill K, Zaid M, Kumar S Sci Rep. 2023; 13(1):16420.

PMID: 37775650 PMC: 10541452. DOI: 10.1038/s41598-023-41942-4.


Rodent Models of Dilated Cardiomyopathy and Heart Failure for Translational Investigations and Therapeutic Discovery.

Ponzoni M, Coles J, Maynes J Int J Mol Sci. 2023; 24(4).

PMID: 36834573 PMC: 9963155. DOI: 10.3390/ijms24043162.